158 related articles for article (PubMed ID: 17443645)
1. Prospective study of depression and fatigue in men with advanced prostate cancer receiving hormone therapy.
Pirl WF; Greer JA; Goode M; Smith MR
Psychooncology; 2008 Feb; 17(2):148-53. PubMed ID: 17443645
[TBL] [Abstract][Full Text] [Related]
2. A randomised, double-blind study comparing the addition of bicalutamide with or without dutasteride to GnRH analogue therapy in men with non-metastatic castrate-resistant prostate cancer.
Chu FM; Sartor O; Gomella L; Rudo T; Somerville MC; Hereghty B; Manyak MJ
Eur J Cancer; 2015 Aug; 51(12):1555-69. PubMed ID: 26048455
[TBL] [Abstract][Full Text] [Related]
3. Comment on "secondary chemoprevention of localized prostate cancer by short-term androgen deprivation to select indolent tumors suitable for active surveillance: a prospective pilot study".
de la Taille A
World J Urol; 2014 Dec; 32(6):1625-6. PubMed ID: 24413818
[No Abstract] [Full Text] [Related]
4. The Association of A Number of Risk Factors With Depression in Patients With Prostate Cancer Undergoing Androgen Deprivation Therapy.
Kim CH; Kim KT; Oh JK; Chung KJ; Kim TB; Jung H; Yoon SJ; Kim KH
Urol J; 2018 May; 15(3):104-108. PubMed ID: 29388185
[TBL] [Abstract][Full Text] [Related]
5. Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancer.
Smith MR; Lee H; Fallon MA; Nathan DM
Urology; 2008 Feb; 71(2):318-22. PubMed ID: 18308111
[TBL] [Abstract][Full Text] [Related]
6. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
[TBL] [Abstract][Full Text] [Related]
7. Bicalutamide alone prior to brachytherapy achieves cytoreduction that is similar to luteinizing hormone-releasing hormone analogues with less patient-reported morbidity.
Petit JH; Gluck C; Kiger WS; Henry DL; Karasiewicz C; Talcott J; Berg S; Holupka E; Kaplan I
Urol Oncol; 2008; 26(4):372-7. PubMed ID: 18367113
[TBL] [Abstract][Full Text] [Related]
8. The Clinical Significance of Bone Mineral Density Changes Following Long-Term Androgen Deprivation Therapy in Localized Prostate Cancer Patients.
Khriguian J; Tsui JMG; Vaughan R; Kucharczyk MJ; Nabid A; Bettahar R; Vincent L; Martin AG; Jolicoeur M; Yassa M; Barkati M; Igidbashian L; Bahoric B; Archambault R; Villeneuve H; Mohiuddin M; Niazi T
J Urol; 2021 Jun; 205(6):1648-1654. PubMed ID: 33577365
[TBL] [Abstract][Full Text] [Related]
9. Re: The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer.
Gardiner RA; Nicol DL; Green HJ; Yaxley J; Watson R; Mactaggart P; Headley BC; Swanson C; Pakenham KI
J Urol; 2004 Aug; 172(2):774; author reply 774-5. PubMed ID: 15247782
[No Abstract] [Full Text] [Related]
10. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
[TBL] [Abstract][Full Text] [Related]
11. Anaemia following initiation of androgen deprivation therapy for metastatic prostate cancer: a retrospective chart review.
Curtis KK; Adam TJ; Chen SC; Pruthi RK; Gornet MK
Aging Male; 2008 Dec; 11(4):157-61. PubMed ID: 18937151
[TBL] [Abstract][Full Text] [Related]
12. Secondary chemoprevention of localized prostate cancer by short-term androgen deprivation to select indolent tumors suitable for active surveillance: a prospective pilot phase II study.
Cussenot O; Cornu JN; Drouin SJ; Mozer P; Egrot C; Vaessen C; Haab F; Bitker MO; RouprĂȘt M
World J Urol; 2014 Apr; 32(2):545-50. PubMed ID: 24166289
[TBL] [Abstract][Full Text] [Related]
13. The effect of androgen deprivation therapy on fasting serum lipid and glucose parameters.
Yannucci J; Manola J; Garnick MB; Bhat G; Bubley GJ
J Urol; 2006 Aug; 176(2):520-5. PubMed ID: 16813881
[TBL] [Abstract][Full Text] [Related]
14. Prostate-specific antigen half-life and pretreatment prostate-specific antigen: crucial predictors for prostate-specific antigen trend in delayed-combined androgen blockade therapy.
Soga N; Onishi T; Arima K; Sugimura Y
Int J Urol; 2007 Mar; 14(3):192-6; discussion 197. PubMed ID: 17430253
[TBL] [Abstract][Full Text] [Related]
15. Effects of flutamide as a second-line agent for maximum androgen blockade of hormone refractory prostate cancer.
Nishimura K; Arichi N; Tokugawa S; Yoshioka I; Kishikawa H; Ichikawa Y
Int J Urol; 2007 Mar; 14(3):264-7. PubMed ID: 17430272
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular disease risk and androgen deprivation therapy in patients with localised prostate cancer: a prospective cohort study.
Haque R; UlcickasYood M; Xu X; Cassidy-Bushrow AE; Tsai HT; Keating NL; Van Den Eeden SK; Potosky AL
Br J Cancer; 2017 Oct; 117(8):1233-1240. PubMed ID: 29017178
[TBL] [Abstract][Full Text] [Related]
17. Clinical research of Tashinone IIA combined with endocrine therapy in treating advanced-stage prostate cancer.
Yang J; Wang Z; Song L; Tian F; Yu Z; Li F; Tang L
Cell Biochem Biophys; 2014 Jul; 69(3):503-7. PubMed ID: 24526351
[TBL] [Abstract][Full Text] [Related]
18. Residual prostate cancer in patients treated with endocrine therapy with or without radical radiotherapy: a side study of the SPCG-7 randomized trial.
Solberg A; Haugen OA; Viset T; Bergh A; Tasdemir I; Ahlgren G; Widmark A; Angelsen A
Int J Radiat Oncol Biol Phys; 2011 May; 80(1):55-61. PubMed ID: 20598453
[TBL] [Abstract][Full Text] [Related]
19. Analysis of the lipid profile and atherogenic risk during androgen deprivation therapy in prostate cancer patients.
Salvador C; Planas J; Agreda F; Placer J; Trilla E; Lopez MA; Morote J
Urol Int; 2013; 90(1):41-4. PubMed ID: 23235105
[TBL] [Abstract][Full Text] [Related]
20. The long-term results with delayed-combined androgen blockade therapy in local or locally advanced prostate cancer.
Soga N; Hori Y; Ogura Y; Hayashi N; Sugimura Y
Jpn J Clin Oncol; 2012 Jun; 42(6):534-40. PubMed ID: 22438406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]